RAD51 is an essential component for fixing radiation-induced DSBs as part of HR, and germline RAD51 mutations are associated with a 10-20 percent lifetime risk in women for ovarian, fallopian tube, or primary peritoneal cancer and a 30% risk for breast cancer (25). This evidence concerns the gene RAD51 and breast cancer.